Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMRO ELSHOURY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417398975
CMS profile
6352301
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$107,085.68

98 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $92,862.00 32
Travel and Lodging $12,758.48 45
Food and Beverage $1,465.20 21

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Blueprint Medicines Corporation $107,085.68 98

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMRO ELSHOURY

NPI 1417398975 · CMS profile ID 6352301

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417398975?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMRO ELSHOURY, NPI 1417398975, CMS profile ID 6352301. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417398975?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AMRO ELSHOURY, NPI 1417398975, CMS profile ID 6352301. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417398975?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AMRO ELSHOURY, NPI 1417398975, CMS profile ID 6352301, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417398975?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

98 matching records · $107,085.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 98 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–98 of 98.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Blueprint Medicines Corporation $415.8504/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439784 CMS
Blueprint Medicines Corporation $102.4204/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439800 CMS
Blueprint Medicines Corporation $783.4604/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439764 CMS
Blueprint Medicines Corporation $146.3104/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439768 CMS
Blueprint Medicines Corporation $74.0004/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439766 CMS
Blueprint Medicines Corporation $344.5204/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439758 CMS
Blueprint Medicines Corporation $80.0004/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439762 CMS
Blueprint Medicines Corporation $116.9904/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439786 CMS
Blueprint Medicines Corporation $55.5504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439760 CMS
Blueprint Medicines Corporation $25.5104/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439714 CMS
Blueprint Medicines Corporation $3,080.0004/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439716 CMS
Blueprint Medicines Corporation $79.6804/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439718 CMS
Blueprint Medicines Corporation $7.3304/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439720 CMS
Blueprint Medicines Corporation $6,468.0004/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439722 CMS
Blueprint Medicines Corporation $108.4904/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439724 CMS
Blueprint Medicines Corporation $1,232.0004/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439726 CMS
Blueprint Medicines Corporation $488.1004/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439728 CMS
Blueprint Medicines Corporation $199.3004/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439730 CMS
Blueprint Medicines Corporation $767.9603/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439732 CMS
Blueprint Medicines Corporation $80.0003/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439734 CMS
Blueprint Medicines Corporation $488.1003/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439736 CMS
Blueprint Medicines Corporation $112.8903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439738 CMS
Blueprint Medicines Corporation $1,232.0003/27/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439740 CMS
Blueprint Medicines Corporation $1,232.0003/27/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439748 CMS
Blueprint Medicines Corporation $1,232.0003/27/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439750 CMS
Blueprint Medicines Corporation $1,232.0003/14/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439742 CMS
Blueprint Medicines Corporation $4,620.0003/06/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439626 CMS
Blueprint Medicines Corporation $57.3603/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439628 CMS
Blueprint Medicines Corporation $49.5503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439630 CMS
Blueprint Medicines Corporation $222.5302/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439632 CMS
Blueprint Medicines Corporation $633.2302/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439634 CMS
Blueprint Medicines Corporation $80.0002/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439636 CMS
Blueprint Medicines Corporation $121.1502/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439638 CMS
Blueprint Medicines Corporation $3,696.0002/21/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439640 CMS
Blueprint Medicines Corporation $347.1002/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439642 CMS
Blueprint Medicines Corporation $86.9202/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439644 CMS
Blueprint Medicines Corporation $6,468.0002/14/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439646 CMS
Blueprint Medicines Corporation $227.1602/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439648 CMS
Blueprint Medicines Corporation $30.0002/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439650 CMS
Blueprint Medicines Corporation $258.7702/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439652 CMS
Blueprint Medicines Corporation $496.2002/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439704 CMS
Blueprint Medicines Corporation $80.0002/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439706 CMS
Blueprint Medicines Corporation $216.1702/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439708 CMS
Blueprint Medicines Corporation $560.9602/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439710 CMS
Blueprint Medicines Corporation $80.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439712 CMS
Blueprint Medicines Corporation $4.9102/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439620 CMS
Blueprint Medicines Corporation $1,232.0002/07/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439744 CMS
Blueprint Medicines Corporation $1,232.0001/24/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147439746 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,112.50 2
PY2021 $455.57 3
PY2022 $33,388.15 35
PY2023 $66,295.38 73
PY2024 $107,085.68 98
PY2025 $2,464.00 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $169,662.10 17
PY2020 Principal investigator $32,577.19 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Blueprint Medicines Corporation $16,822.92 11/24/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927637
Principal investigator 1 Blueprint Medicines Corporation $5,767.72 10/28/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927631
Principal investigator 1 Blueprint Medicines Corporation $5,685.82 10/14/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927629
Principal investigator 1 ABBVIE INC. $1,401.40 09/15/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis No dispute reported 06/30/2026 792475673
Principal investigator 1 ABBVIE INC. $13,035.45 07/29/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis No dispute reported 06/30/2026 792470617
Principal investigator 1 Blueprint Medicines Corporation $12,673.61 07/29/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927613
Principal investigator 1 Blueprint Medicines Corporation $4,420.37 06/24/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927603
Principal investigator 1 Blueprint Medicines Corporation $12,673.61 05/27/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927477
Principal investigator 1 Blueprint Medicines Corporation $3,636.58 05/13/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927475
Principal investigator 1 Blueprint Medicines Corporation $3,125.00 05/06/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927595
Principal investigator 1 Blueprint Medicines Corporation $17,298.21 04/22/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927473
Principal investigator 1 Blueprint Medicines Corporation $25,614.18 03/25/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927459
Principal investigator 1 Blueprint Medicines Corporation $4,313.04 03/25/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927461
Principal investigator 1 Blueprint Medicines Corporation $3,125.00 02/25/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927433
Principal investigator 1 Blueprint Medicines Corporation $1,750.00 02/18/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927435
Principal investigator 1 Blueprint Medicines Corporation $34,437.45 02/11/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927431
Principal investigator 1 Blueprint Medicines Corporation $3,881.74 01/14/2021 Non-covered Recipient Entity
HEALTH RESEARCH INC
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis No dispute reported 06/30/2026 848927421